Association Between SGLT2 Inhibitor Treatment and Diabetic Ketoacidosis and Mortality in People With Type 2 Diabetes Admitted to Hospital With COVID-19.

Kamlesh Khunti F MedSci Yuehuan Chung Jim Davies Benjamin C T Field Sophie Harris Mikhail Naum KosiborodDinesh NagiParth Narendran Dipesh Patel Robert E J Ryder Kinga A Várnai Sarah D Wild Emma G Wilmot Rustam D Reanull null

Published in: Diabetes care (2022)

We demonstrate a low risk of DKA and high mortality rate in people with T2D admitted to hospital with COVID-19 and limited power, but no evidence, of increased risk of DKA or in-hospital mortality associated with prescription of SGLT2is.

Keyphrases

coronavirus disease
sars cov
cardiovascular events
healthcare
acute care
risk factors
type diabetes
adverse drug
respiratory syndrome coronavirus
coronary artery disease
cardiovascular disease
emergency department